RNA, U6 small nuclear 257, pseudogene (RNU6-257P)

"RNA, U6 small nuclear 257, pseudogene" (abbreviated RNU6-257P) is a **pseudogene** derived from the U6 small nuclear RNA (snRNA) gene family. U6 snRNA is an essential component of the spliceosome complex, which catalyzes removal of introns from pre-mRNA during RNA splicing in the nucleus of eukaryotic cells[3][1]. However, RNU6-257P itself is a **pseudogene**, meaning it is a non-functional genomic DNA sequence that resembles a functional gene but lacks protein-coding potential and is not believed to be transcribed into a functional RNA molecule[5]. Pseudogenes of U6 and related snRNAs, including RNU6-257P, are the result of retrotransposition events, often mediated by LINE-1 elements, and are present in many copies within vertebrate genomes[5][3]. These pseudogenes do not contribute to the formation of the spliceosome and have no established role in cellular processes, disease, or drug response. RNU6-257P is *not* considered a therapeutic target, receptor, enzyme, transporter, or functionally relevant non-coding RNA[5]. The existence of U6 snRNA pseudogenes can serve as markers of genome retrotransposition activity across species and evolutionary history, but does not confer any known functional role to the RNA or its corresponding DNA locus[5]. ### Additional Notes: - RNU6-257P's **status as a pseudogene** and not a protein-coding gene or functional ncRNA means it should *not* be catalogued as a valid molecular target for drug discovery or therapeutic intervention. - "RNU6-257P" follows a naming convention for processed pseudogenes of the snRNA U6 family, and these are distinct from functional "U6 snRNA" genes and molecules[3][5]. - There is nothing indicating the abbreviation or name is misspelled, but this entry is **not a target** and should be excluded from structured drug-target lists. - No known drugs, mechanisms of action, biomarker value, or safety issues are associated with RNU6-257P.

Other names

RNU6-257PRNA, U6 small nuclear 257, pseudogene